APLSApellis Pharmaceuticals, Inc.

Nasdaq apellis.com


$ 40.57 $ -1.44 (-3.43 %)    

Thursday, 23-May-2024 13:07:47 EDT
QQQ $ 454.82 $ -3.91 (-0.85 %)
DIA $ 398.57 $ -4.08 (-1.03 %)
SPY $ 530.36 $ -3.58 (-0.67 %)
TLT $ 91.26 $ -0.82 (-0.89 %)
GLD $ 225.37 $ -2.57 (-1.17 %)
$ 43.6
$ 42.01
$ 0.00 x 0
$ 40.65 x 224
$ 40.29 - $ 42.25
$ 19.83 - $ 94.75
1,259,809
na
5.36B
$ 0.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 07-31-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-21-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 04-28-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-02-2020 09-30-2020 10-Q
16 07-30-2020 06-30-2020 10-Q
17 04-29-2020 03-31-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 07-31-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 02-26-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 07-31-2018 06-30-2018 10-Q
25 04-30-2018 03-31-2018 10-Q
26 03-19-2018 12-31-2017 10-K
27 12-20-2017 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wells-fargo-maintains-equal-weight-on-apellis-pharmaceuticals-lowers-price-target-to-48

Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Equal-Weight and lowers the price t...

 apellis-pharmaceuticals-refinances-existing-debt-with-up-to-475m-non-dilutive-credit-facility

Apellis received $375 million in funding at close, with ability to access an additional $100 millionMajority of initial proceed...

 citigroup-maintains-buy-on-apellis-pharmaceuticals-lowers-price-target-to-60

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target f...

 hc-wainwright--co-reiterates-buy-on-apellis-pharmaceuticals-maintains-92-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 p...

 ubs-maintains-buy-on-apellis-pharmaceuticals-lowers-price-target-to-85

UBS analyst Eliana Merle maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $89 to ...

 needham-reiterates-buy-on-apellis-pharmaceuticals-maintains-85-price-target

Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.

 apellis-pharmaceuticals-q1-eps-054-misses-053-estimate-sales-17232m-beat-16335m-estimate

Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimat...

 mizuho-maintains-neutral-on-apellis-pharmaceuticals-lowers-price-target-to-52

Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and lowers the price target ...

 hc-wainwright--co-reiterates-buy-on-apellis-pharmaceuticals-maintains-92-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 p...

 needham-reiterates-buy-on-apellis-pharmaceuticals-maintains-85-price-target

Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.

 wedbush-maintains-neutral-on-apellis-pharmaceuticals-lowers-price-target-to-57

Wedbush analyst Laura Chico maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and lowers the price target from ...

 hc-wainwright--co-reiterates-buy-on-apellis-pharmaceuticals-maintains-92-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 p...

 needham-reiterates-buy-on-apellis-pharmaceuticals-maintains-85-price-target

Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.

 mizuho-maintains-neutral-on-apellis-pharmaceuticals-maintains-60-price-target

Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and maintains $60 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION